nanthealth | NantOmics

NantHealth and NantOmics Announce GPS Cancer® Platform May Improve Clinical Trial Design of Combination Strategies by Identifying Previously Unrecognized Cancer Type Specific Associations between Immunoregulatory Molecules and Genomic Mutations

by Jen Hodson | Feb 19, 2020 | Press Releases

Findings Presented at the ASCO-SITC 2020 Clinical Immuno-Oncology Symposium Orlando, FL and Culver City, CA – February 6, 2020 – NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in...

NantHealth and NantOmics Reveal a Novel AI Based Machine-Learning Digital Pathology Software for Lung Cancer by Identifying Tumor Infiltrating Killer Cells from Whole Slide Images

by Jen Hodson | Jan 29, 2020 | Press Releases

Derived from deep-learning models, the findings demonstrate novel AI methods of identifying tumor-infiltrating lymphocytes (TILs) in lung cancers Burlingame, CA – January 28, 2020: NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized...